Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 09:50:00 11/12/2025 pm IST			5-day change	1st Jan Change
2,046.00 ^DKK	+2.74%		+1.14%	+37.09%

02:50am	Genmab A/S - Special Call
10/12	BillionToOne Q3 Swings to Profit, Revenue Rises; Shares Fall After Hours	MT

RBC lowers target price for Genmab to DKK 2,000 (2,300), reiterates outperform rating - BN

Published on 05/30/2025 at 09:50 am IST

Finwire - Translated by Marketscreener - See original

Genmab A/S

+2.74%

RBC lowers target price for Genmab to DKK 2,000 (2,300), reiterates outperform rating - BN

Latest news about Genmab A/S

02:50am	Genmab A/S - Special Call
10/12	BillionToOne Q3 Swings to Profit, Revenue Rises; Shares Fall After Hours	MT
09/12	Genmab shares encouraging early-stage data on epcoritamab for RT patients	RE
09/12	Genmab Presents Promising Data for Epcoritamab in Richter's Transformation	FW
09/12	Genmab Epcoritamab Achieves Up to 73% Complete Response Across Richter Transformation Trial Arms	MT
08/12	Genmab announces data from multiple clinical trials	RE
08/12	Genmab presents phase 3 data from EPCORE FL-1 trial	RE
08/12	Genmab Reports Strong Phase 3 Data for Epkincly Combination	FW
08/12	JP Morgan Raises Genmab Price Target to 2,050 Danish Kroner (from 1,650), Maintains Neutral Rating - BN	FW
05/12	Genmab A/S Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 09:45 AM
04/12	Genmab Closes $2.5 Billion Senior Notes Offering	MT
04/12	Genmab A/S and Genmab Finance LLC Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes	CI
02/12	European Equities Close Mixed in Tuesday Trading; Euro Area Inflation Rises 2.2% in November	MT
02/12	Genmab, Pfizer's Cervical Cancer Drug Gets UK Regulatory Nod	MT
02/12	Genmab's Cervical Cancer Drug Gets UK Regulatory Approval	MT
22/11	Genmab A/S Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 12:00 PM
19/11	FDA Approves Genmab's Combination Therapy for Follicular Lymphoma	FW
19/11	Genmab Unit Prices $2.5 Billion Senior Notes Offering	MT
19/11	Genmab announces pricing of private offering of senior secured notes and senior unsecured notes	RE
19/11	Genmab Reports FDA Approval for Epkinly in Follicular Lymphoma	MT
19/11	Genmab Secures US Approval for Follicular Lymphoma Combo Therapy	MT
18/11	Genmab A/S Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma	CI
14/11	Kepler Cheuvreux Kicks Off Genmab Coverage at Hold	MT
11/11	Fitch Assigns First-time Rating to Genmab with Stable Outlook	MT
10/11	Genmab Plans $2.5 Billion Notes Offering, Launches Syndication of $2 Billion Term Loan	MT

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (80.6%); - income from research and development (9.3%); - other (10.1%): primarily income from partnership agreement. At the end of 2024, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Net sales are distributed geographically as follows: Denmark (91.9%), the United States (4.2%) and Japan (3.9%).

Employees

2,681

Sector

Biotechnology & Medical Research

Calendar

09:30pm - R&D Day

More about the company